Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity

[1]  R. Donato,et al.  S100B/RAGE-dependent activation of microglia via NF-κB and AP-1 Co-regulation of COX-2 expression by S100B, IL-1β and TNF-α , 2010, Neurobiology of Aging.

[2]  J. Moreno,et al.  Suppression of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Nitric-Oxide Synthase 2 Expression in Astrocytes by a Novel Diindolylmethane Analog Protects Striatal Neurons against Apoptosis , 2009, Molecular Pharmacology.

[3]  K. Tracey,et al.  The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage , 2008, The Journal of Neuroscience.

[4]  J. Moreno,et al.  Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP , 2008, Brain Research.

[5]  Howard E. Gendelman,et al.  Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.

[6]  H. Kato,et al.  Time dependent alterations of co-localization of S100β and GFAP in the MPTP-treated mice , 2006, Journal of Neural Transmission.

[7]  Isidre Ferrer,et al.  Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease , 2005, Journal of neuropathology and experimental neurology.

[8]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[9]  Vladimir V. Frolkis,et al.  Neurobiology of Aging , 2019, Psychobiology of Behaviour.

[10]  V. Arolt,et al.  S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury , 2004, Neuroscience.

[11]  J. Schneider,et al.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.

[12]  J. Schulz,et al.  Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation , 2004, Cell and Tissue Research.

[13]  M. Vila,et al.  L‐3‐hydroxyacyl‐CoA dehydrogenase II protects in a model of Parkinson's disease , 2004, Annals of neurology.

[14]  L. J. Eldik,et al.  Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1β production , 2004, Neurobiology of Aging.

[15]  Pasko Rakic,et al.  JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Dichgans,et al.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. , 2004, Journal of neurochemistry.

[17]  J. Dichgans,et al.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation , 2003 .

[18]  T. Araki,et al.  Expression of S‐100 protein is related to neuronal damage in MPTP‐treated mice , 2003, Glia.

[19]  M. Vila,et al.  NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Dong-Kug Choi,et al.  Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Schmidt,et al.  Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. , 2002, Advanced drug delivery reviews.

[22]  H. Freeze,et al.  N‐Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth , 2002, Journal of neurochemistry.

[23]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[24]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[25]  L. J. Eldik,et al.  S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia , 2001, Neurochemistry International.

[26]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[27]  F. Weih,et al.  Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. , 2001, Neuroreport.

[28]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[29]  H. Huttunen,et al.  Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.

[30]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[31]  J. Dichgans,et al.  Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.

[32]  K. Unsicker,et al.  GDNF and NT-4 Protect Midbrain Dopaminergic Neurons from Toxic Damage by Iron and Nitric Oxide , 2000, Experimental Neurology.

[33]  S. Barger,et al.  S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.

[34]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[35]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[36]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[37]  R. Donato,et al.  Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. , 1999, Biochimica et biophysica acta.

[38]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[39]  E. Hirsch,et al.  FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.

[40]  C. Sen,et al.  Nuclear factor kappa B activity in response to oxidants and antioxidants. , 1999, Methods in enzymology.

[41]  E. Hirsch,et al.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[42]  C. Kerkhoff,et al.  Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). , 1998, Biochimica et biophysica acta.

[43]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[44]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Kaltschmidt,et al.  NF-kB: a crucial transcription factor for glial and neuronal cell function , 1997, Trends in Neurosciences.

[46]  C. Kaltschmidt,et al.  NF-kappa B: a crucial transcription factor for glial and neuronal cell function. , 1997, Trends in neurosciences.

[47]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[48]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[49]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[50]  D. Baltimore,et al.  Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. , 1995, Nature.

[51]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[52]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[53]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[54]  D. Reis,et al.  Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum , 1981, Brain Research.

[55]  V. Tennyson,et al.  5-Hydroxydopamine 'tagged' neuronal boutons in rabbit neostriatum: interrelationship between vesicles and axonal membrane. , 1974, Brain research.